Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$19.70
-$12.67(-64.31%)
At close: 4:00 PM EDT
$19.70
-$12.67(-64.31%)
Day’s Range― - ―
52-Week Range$2.96 - $40.37
Previous CloseN/A
Volume8.05M
Average Volume (3M)1.65M
Market Cap
$433.14M
Enterprise Value$1.25K
Total Cash (Recent Filing)$237.93M
Total Debt (Recent Filing)$91.05M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding58,138,990
10 Day Avg. Volume1,657,460
30 Day Avg. Volume1,646,431
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.50Price Target Upside-46.70% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$102.23M
Bulls Say, Bears Say
Bulls Say
HOPE-3 Primary EfficacyThe statistically significant primary endpoint provides a defined clinical value proposition for Deramiocel in DMD. If confirmed through FDA review, it could support approval for an upper-limb skeletal-muscle indication and establish a focused commercial opportunity.
Clinical Experience And SafetyBroad treatment exposure and long-term follow-up strengthen the program’s safety database and reduce clinical execution uncertainty. This experience can support regulatory discussions, physician confidence and future development of related cell- and exosome-based therapies.
Manufacturing And Cash ReadinessOperational internal manufacturing can improve control over supply, quality and launch execution if approval is obtained. The sizable liquidity reserve also gives Capricor flexibility to fund regulatory, manufacturing and commercial preparations over the near term.
Bears Say
No Revenue And Widening LossesCapricor has not yet demonstrated commercial scale and remains dependent on a successful product launch to create revenue. Rising operating costs and widening losses increase the amount of capital required before the business can become self-sustaining.
Regulatory Approval UncertaintyThe negative advisory vote weakens the case for the originally targeted cardiomyopathy use and creates approval and label uncertainty. Although non-binding, it may narrow the initial market and require additional data, analysis or regulatory negotiation.
Persistent Cash Burn And Rising LeverageSustained negative cash generation means Capricor may need additional financing before reaching commercialization or profitability. Rising debt adds obligations to a loss-making business and could reduce financial flexibility if regulatory timelines or launch costs extend.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $2.96 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $433.14M.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 90 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.589 by -$0.111.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Overvalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 58,138,990 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.589. Following the earnings report the stock price went up 57.957%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.50 (-46.70% Downside)
$10.50 (-46.70% Downside)
Blogger Sentiment
Bullish
CAPR Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.2%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Bearish
Bullish news 36%
Bearish news 64%
Bearish news 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
204.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (CAPR) is a biotechnology company focused on developing cell- and exosome-based therapeutics for rare diseases, with its lead clinical program centered on Duchenne muscular dystrophy (DMD). The company’s development efforts include its cell therapy candidate (CAP-1002) and related biologic/exosome platform programs aimed at modulating inflammation and promoting tissue repair, and it operates primarily as a clinical-stage drug developer.
CAPR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and regulatory progress (Lancet publication, statistically significant primary HOPE‑3 endpoint for upper limb function, established safety exposure, operational in‑house manufacturing and $237.9M cash) against substantial near‑term challenges (AdCom vote against the cardiomyopathy question, mixed secondary endpoint results, no revenue, rising operating expenses and widening losses, a Form 483 observation, paused non‑Daramycin pipeline work, and an ongoing commercial dispute with NS Pharma). Management has a clear path to submit an amendment focused on the primary skeletal muscle indication and the FDA indicated willingness to review it, but regulatory and financial risks remain in the near term.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$10.50
▼(-46.70% Downside)
Technical Analysis
Ownership Overview
0.93% Insiders
8.15% Mutual Funds
31.74% Other Institutional Investors
45.25% Public Companies and
Individual Investors